# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and lowers the price target fr...
Initiated activities to reduce annualized run-rate operating expenses and the Company expects to achieve above the high end of ...
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $...
JP Morgan analyst Rachel Vatnsdal downgrades Pacific Biosciences (NASDAQ:PACB) from Overweight to Neutral.
Goldman Sachs analyst Matthew Sykes maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and lowers the price target f...
Bernstein analyst Eve Burstein maintains Pacific Biosciences (NASDAQ:PACB) with a Outperform and lowers the price target fro...